down arrow

Soligenix, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8342235053
USD
1.63
0.05 (3.16%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.511.67

52 Week

1.096.23
Valuation
Technical
Day's Volume

CASH

241.46 k

Shareholding (Mar 2025)

FII

0.04%

Held by 4 FIIs

DII

98.75%

Held by 1 DIIs

Promoter

0.00%

How big is Soligenix, Inc.?

22-Jun-2025

As of Jun 18, Soligenix, Inc. has a market capitalization of 5.88 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -9.59 million over the latest four quarters.

Market Cap: As of Jun 18, Soligenix, Inc. has a market capitalization of 5.88 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Soligenix, Inc. reported net sales of 0.00 million and a net profit of -9.59 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4.12 million and total assets of 8.97 million.

Read More

What does Soligenix, Inc. do?

22-Jun-2025

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, with a market cap of $5.88 million and a recent net profit of -$3 million. The company has no dividend yield and is currently loss-making.

Overview:<BR>Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 5.88 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -2.00<BR>Return on Equity: -276.72%<BR>Price to Book: 1.63<BR><BR>Contact Details:<BR>Address: 29 Emmons Dr Ste B10, PRINCETON NJ: 08540-5950<BR>Tel: 1 609 5388200<BR>Website: https://www.soligenix.com/

Read More

Who are in the management team of Soligenix, Inc.?

22-Jun-2025

As of March 2022, the management team of Soligenix, Inc. includes Dr. Christopher Schaber as Chairman, President, and CEO, along with independent directors Mr. Gregg Lapointe, Ms. Diane Parks, Dr. Robert Rubin, and Dr. Jerome Zeldis.

As of March 2022, the management team of Soligenix, Inc. includes Dr. Christopher Schaber, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the Board of Directors features independent directors Mr. Gregg Lapointe, Ms. Diane Parks, Dr. Robert Rubin, and Dr. Jerome Zeldis.

Read More

Is Soligenix, Inc. overvalued or undervalued?

25-Jun-2025

As of August 13, 2021, Soligenix, Inc. is considered overvalued at $1.65 due to its negative P/E ratio, high Price to Book Value of 1.74, and unsustainable ROCE of 295.01%, especially when compared to peers with worse EV to EBITDA ratios.

As of 13 August 2021, the valuation grade for Soligenix, Inc. has moved from risky to does not qualify, indicating a shift in the assessment of its financial health. The company appears to be overvalued given its current price of $1.65, especially when considering its negative P/E ratio due to being loss-making, a Price to Book Value of 1.74, and an extraordinarily high ROCE of 295.01%, which is not sustainable. <BR><BR>In comparison to its peers, Soligenix's EV to EBITDA stands at 0.09, while Inhibikase Therapeutics, Inc. has a similar valuation grade with an EV to EBITDA of -0.9168, and Aileron Therapeutics, Inc. shows an EV to EBITDA of -1.2239. These comparisons suggest that Soligenix is not only struggling relative to its industry but also lacks the financial metrics to justify its current valuation. Overall, the analysis indicates that Soligenix, Inc. is overvalued in the current market context.

Read More

Is Soligenix, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Soligenix, Inc. shows a mildly bullish technical trend with positive momentum indicators, but it has underperformed the S&P 500 significantly over the past month and year.

As of 11 September 2025, the technical trend for Soligenix, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are bullish, supporting the upward trend. However, the Bollinger Bands show a mildly bullish stance on the weekly chart but bearish on the monthly, suggesting mixed signals. The KST is bullish on the weekly and mildly bullish on the monthly, while the OBV is mildly bearish on the weekly, indicating some selling pressure. Overall, the technical stance is mildly bullish, but caution is warranted due to the mixed indicators.<BR><BR>In terms of performance, Soligenix has underperformed the S&P 500 across multiple periods, with a 1-month return of -44.35% compared to the S&P 500's 2.33%, and a 1-year return of -31.17% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.73

stock-summary
Return on Equity

-599.15%

stock-summary
Price to Book

6.23

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-47.08%
0%
-47.08%
6 Months
-16.41%
0%
-16.41%
1 Year
-49.54%
0%
-49.54%
2 Years
-86.04%
0%
-86.04%
3 Years
-98.79%
0%
-98.79%
4 Years
-99.15%
0%
-99.15%
5 Years
-99.7%
0%
-99.7%

Soligenix, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Soligenix, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Soligenix, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages are bullish, supporting the upward trend. However, the Bollinger Bands show a mildly bullish stance on the weekly chart but bearish on the monthly, suggesting mixed signals. The KST is bullish on the weekly and mildly bullish on the monthly, while the OBV is mildly bearish on the weekly, indicating some selling pressure. Overall, the technical stance is mildly bullish, but caution is warranted due to the mixed indicators. In terms of performance, Soligenix has underperformed the S&P 500 across multiple periods, with a 1-month return of -44.35% compared to the S&P 500's 2.33%, and a 1-year return of -31.17% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
5.91%
EBIT to Interest (avg)
-12.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.00
Sales to Capital Employed (avg)
0.03
Tax Ratio
3.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.40%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.74
EV to EBIT
0.09
EV to EBITDA
0.09
EV to Capital Employed
0.25
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
295.01%
ROE (Latest)
-276.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.21%)

Foreign Institutions

Held by 4 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 15.62% vs -6.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-3.30",
          "chgp": "15.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-3.20",
          "chgp": "15.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -36.07% vs 55.80% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.60",
          "val2": "-8.40",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-0.20",
          "chgp": "400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.30",
          "val2": "-6.10",
          "chgp": "-36.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.80
-3.30
15.15%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.70
-3.20
15.62%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 15.62% vs -6.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.60
-8.40
-14.29%
Interest
0.00
0.00
Exceptional Items
0.60
-0.20
400.00%
Consolidate Net Profit
-8.30
-6.10
-36.07%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -36.07% vs 55.80% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Soligenix, Inc. stock-summary
stock-summary
Soligenix, Inc.
Pharmaceuticals & Biotechnology
Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two business segments: Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease. CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Company Coordinates stock-summary
Company Details
29 Emmons Dr Ste B10 , PRINCETON NJ : 08540-5950
stock-summary
Tel: 1 609 5388200
stock-summary
https://www.soligenix.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."